Mining bacterial genomes hidden pharmaceutical treasure

Mining bacterial genomes for hidden pharmaceutical treasure

5:52 AM, 12th April 2017
Mining bacterial genomes for hidden pharmaceutical treasure
Researchers used CRISPR technology to activate silent gene clusters in Streptomyces bacteria, a potential treasure trove of new classes of drugs. Clockwise from back middle: graduate student Behnam Enghiad, postdoctoral researcher Shangwen Luo, graduate student Tajie Luo and professor Huimin Zhao.

CHAMPAIGN, US: In the fight against disease, many weapons in the medicinal arsenal have been plundered from bacteria themselves. Using CRISPR-Cas9 gene-editing technology, researchers have now uncovered even more potential treasure hidden in silent genes.

A new study from researchers at the University of Illinois and colleagues at the Agency for Science, Technology and Research (A*STAR) in Singapore used CRISPR technology to turn on unexpressed, or “silent,” gene clusters in Streptomyces, a common class of bacteria that naturally produce many compounds that have already been used as antibiotics, anti-cancer agents and other drugs.

The study, led by chemical and biomolecular engineering professor Huimin Zhao, was published in the journal Nature Chemical Biology.

“In the past, researchers just screened the natural products that bacteria made in the lab to search for new drugs,” Zhao said. “But once whole bacterial genomes were sequenced, we realised that we have only discovered a small fraction of the natural products coded in the genome.

“The vast majority of biosynthetic gene clusters are not expressed under laboratory conditions or are expressed at very low levels. That’s why we call them silent. There are a lot of new drugs and new knowledge waiting to be discovered from these silent gene clusters. They are truly hidden treasures.”

To mine for undiscovered genomic treasure, the researchers first used computational tools to identify silent biosynthetic gene clusters – small groups of genes involved in making chemical products. Then they used CRISPR technology to insert a strong promoter sequence before each gene that they wanted to activate, prompting the cell to make the natural products that the genes clusters coded for.

“This is a less-explored direction with the CRISPR technology. Most CRISPR-related research focuses on biomedical applications, like treating genetic diseases, but we are using it for drug discovery,” Zhao said. His lab was the first to adapt the CRISPR system for Streptomyces. “In the past, it was very difficult to turn on or off a specific gene in Streptomyces species. With CRISPR, now we can target almost any gene with high efficiency.”

The team succeeded in activating a number of silent biosynthetic gene clusters. To look for drug candidates, each product needs to be isolated and studied to determine what it does. As a demonstration, the researchers isolated and determined the structure of one of the novel compounds produced from a silent biosynthetic gene cluster, and found that it has a fundamentally different structure from other Streptomyces-derived drugs – a potential diamond in the rough.

Zhao said such new compounds could lead to new classes of drugs that elude antibiotic resistance or fight cancer from a different angle.

“Antimicrobial resistance is a global challenge. We want to find new modes of action, new properties, so we can uncover new ways to attack cancer or pathogens. We want to identify new chemical scaffolds leading to new drugs, rather than modifying existing types of drugs,” he said.

The US National Institutes of Health and the National Research Foundation of Singapore supported this work.

© University of Illinois News

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


Recipharm appoints new chief financial officer

STOCKHOLM, SWEDEN: Recipharm AB said that it has appointed Henrik Stenqvist as the company’s new executive vice president and chief financial of ...

Read more
Mitsui Chemicals starts up electrolyte solution facilities in Japan

TOKYO, JAPAN: Mitsui Chemicals Inc announced the startup of its electrolyte solution production facilities, which have been built at Nagoya Works to a ...

Read more
IFF acquires food drying industry in US

NEW YORK, US: International Flavors & Fragrances Inc (IFF) said that it has acquired Columbia Phytotechnology LLC, also known as PowderPure, a foo ...

Read more
Fluor selected by Marathon for refinery revamp

IRVING, US: Fluor Corporation (FLR) said that it has been selected by a division of Marathon Petroleum Corporation (Marathon) to execute the engi ...

Read more
KBR settles lengthy commercial dispute with Pemex

HOUSTON, US: KBR Inc (KBR) said that it has settled its decade-long dispute over an almost half billion-judgment relating to the engineering, procurem ...

Read more
Enterprise to build NGL pipeline from Permian to Mont Belvieu, Texas

HOUSTON, US: Enterprise Products Partners LP (EPD) announced the construction of a new 571-mile pipeline to transport natural gas liquids (NGL) from t ...

Read more